PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis

Photodermatology Photoimmunology and Photomedicine

Volumn 15, Issue 1, 1999, Pages 22-27

  Coven, T R ^a   Walters, I B ^a   Cardinale, I ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

8 methoxypsoralen; Psoriasis vulgaris; PUVA; T lymphocytes; Trimethylpsoralen

Indexed keywords

METHOXSALEN; PSORALEN;

APOPTOSIS; ARTICLE; CARCINOGENICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PSORIASIS; PUVA; T LYMPHOCYTE ACTIVATION;

EID: 0032939938     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0781.1999.tb00048.x     Document Type: Article

References (25)

1. Parrish JA, Fitzpatrick TB, Tannenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974: 291: 1207-1211.
2. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuki R, Krueger JG. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in normal and malignant T-lymphocytes. Photochem Photobiol 1996: 63: 566-571.
3. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996: 107: 235-242.
4. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995: 1: 442-447.
5. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxysalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997: 336: 1041-1045.
6. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994: 73: 2759-2764.
7. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988: 91: 120-124.
8. Forman AB, Roenigk HH, Caro WA, Magid ML. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989: 125: 515-519.
9. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E et al. Trioxsalen bath PUVA does not increase the risk of squamous cell skin carcinoma. A joint analysis of 1124 Swedish and Finnish patients followed up for ten years. J Invest Dermatol 1997: 97: 1-2.
10. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Berne B. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. Arch Dermatol 1992: 128: 1341-1344.
11. Lindelof B, Sigurgeirsson B, Tegner E et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991: 338: 91-93.
12. Berne B, Fischer T, Michaelsson G, Noren P. Long-term safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients. Photodermatology 1984: 1: 18-22.
13. Turjanma K, Salo H, Reunala T. Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis. Acta Derm Venereol (Stockh) 1985: 65: 86-89.
14. Salo OP, Lassus A, Taskinen J. Trioxsalen bath plus UVA treatment of psoriasis. Acta Derm Venereol (Stockh) 1981: 61: 551-554.
15. Hannuksela M, Karvonen J. Trioxsalen bath plus UVA effective and safe in the treatment of psoriasis. Br J Dermatol 1978: 99: 703-707.
16. Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol (Stockh) 1976: 56: 383-390.
17. Vallat VP, Gilleaudeau P, Battat L et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J Exp Med 1994: 180: 283-296.
18. Norris DA, Travers JB, Leung DYM. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997: 109: 1-1.
19. Krueger JG, Wolfe JT, Nabeya RT et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995: 182: 2057-2068.
20. Berger CL, Cantor C, Welsh J et al. Comparison of synthetic psoralen derivatives and 8-MOP in the inhibition of lymphocyte proliferation. Ann N Y Acad Sci 1985: 453: 80-90.
21. Vaatainen N, Taskinen J. Penetration of trioxsalen into skin from trioxsalen baths. Arch Dermatol Res 1981: 270: 157-158.
22. Pierard-Franchimont C, Nickels-Read D, Mosbah TB, Estrada JA, Pierard GE. Early dermato-pathological signs during bath-PUVA therapy. J Pathol 1990: 161: 227-231.
23. Koulu LM, Jansen CT. Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. J Am Acad Dermatol 1988: 18: 1053-1059.
24. Koulu L, Jansen CT. Skin photosensitizing and Langerhans' cell depleting activity of topical (bath) PUVA therapy: Comparison of trimethylpsoralen and 8-methoxypsoralen. Acta Derm Venereol (Stockholm) 1983: 63: 137-141.
25. Coven TR, Murphy FP, Gilleaudeau P et al. Trimethylpsoralen (TMP) bath PUVA is a remittive treatment for psoriasis vulgaris: Evidence that epidermal immunocytes are direct targets. Arch Dermatol 1998: 134: 1263-1268.